fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Late breaking data for Bimzelx (bimekizumab) from two year phase III studies in moderate to severe hidradentis suppurativa presented at EADV – UCB

Written by | 9 Oct 2024

UCB, announced the first presentation of two-year data from the Phase III studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating the efficacy and… read more.

UCB announces the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab

Written by | 28 Sep 2024

UCB, a global biopharmaceutical company, announced the presentation of new four-year data in patients with moderate to severe plaque psoriasis treated with bimekizumab, an IL-17A and IL-17F inhibitor…. read more.

UCB to accelerate innovation and strategic partnerships, divesting mature product portfolio in China to CBC Group.

Written by | 2 Sep 2024

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.

First presentations of Bimzelx (bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 – UCB

Written by | 28 Jun 2024

UCB, announced the first presentation of two-year data from the Phase III studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating bimekizumab,… read more.

CHMP positive opinion for two 320 mg device presentations of Bimzelx (bimekizumab) – UCB

Written by | 5 Jun 2024

UCB, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorization for… read more.

UCB presents final open-label extension (fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting

Written by | 13 May 2024

UCB announced the final three-year open-label extension (OLE) study results of Fintepla (fenfluramine) in Dravet syndrome are being presented at the International Child Neurology Congress (ICNC), May 6-10,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.